Trapidil - Sinopia Biosciences
Alternative Names: SB-0107Latest Information Update: 12 Oct 2021
Price :
$50 *
At a glance
- Originator Sinopia Biosciences
- Class Antiparkinsonians; Antiplatelets; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Drug-induced dyskinesia; Parkinson's disease
Most Recent Events
- 12 Oct 2021 Chemical structure information added
- 29 Sep 2021 Phase-I/II clinical trials in Drug-induced dyskinesia in USA (unspecified route) (Sinopia Biosciences pipeline, September 2021)
- 29 Sep 2021 Phase-I/II clinical trials in Parkinson's disease in USA (unspecified route) (Sinopia Biosciences pipeline, September 2021)